  Danh hiệu: MemberGroups ready for retrieval: Thành viên chính thức
Gia nhập: 09-01-2006(UTC)
Bài viết: 219
Được cảm ơn: 1 lần trong 1 bài viết
|
Hôm trước là các Vaccine đang thử nghiệm . Hôm nay , gởi đến các bạn các loại thuốc đang thử nghiệm ,sẽ là liều thuốc có ích cho các bạn bị stress và các bạn đang bệnh ........
À , bây giờ là 9 giờ tối, 3 tiếng nữa là giao thừa, heavenandhell chúc các bạn luôn mạnh khỏe ,hạnh phúc và luôn vững tin vào một tương lai tươi sáng nghen.
Hiện có 3 loại thuốc mới đang thử nghiệm giai đoạn 3 (giai đọan cuối ) ,ngoài ra còn hơn 130 loại nữa đang thử nghiệm , cố lên bạn ơi..........
Lưu ý , loại nào có màu xanh dương là đã ngưng thử nghiệm , còn các loại khác vẫn đang tiếp tục . Tin vui là loại thuốc Mk0518 đang thử nghiệm giai đoạn 3,đây là loại thuốc mà những người tình nguyện sau khi dùng , lượng virus giạm chỉ còn 1%, cá biệt nhiều người không còn dò thấy virus (dù vẫn nhiễm bệnh, có lẽ do lượng virus còn quá ít nên ko dò thấy được.).
Vậy là hy vọng lại tràn trề rồi ha, ăn tết vui nha các bạn ..........Găp lại sau tết nhé ...........
| NRTIs, NNRTIs and Protease Inhibitors |
| Phase of Development |
NRTI |
NNRTI |
PI |
| Preclinical |
BPH-218, bis-phosphonate NRTI, U Pittsburgh
 |
C-8 substituent,
BI
|
AG-1859, Pfizer
|
|
Dinucleoside polyphosphates, NRTI "potentiators"
U Miami
|
GS9148 and GS9148 prodrug, Gilead
 |
GRL-02031, Kumamoto U |
|
DOT-TP, Emory U |
SMP-717,
Advanced Life Sciences
|
UIC02031, Kumamoto U, Japan
|
|
Compound X, nucleotide-competing RTI, Tibotec
|
SMP-610, Advanced Life Sciences
|
SPI-256, Sequoia Pharm |
|
KMMP05, RNase H Inhibitor, NCI
|
S-DABO derivatives (HIV-1 and -2), Fudan U, China |
Beta lactams, University of Debrecen, Hungary
|
|
D-FDOC, Emory Univ. |
Oligodeoxi-nucleotides, U Hospital, Zurich
|
A-681799, Abbott |
|
4-Ed4T, Kagoshima U |
PBO-15c, pyrrolobenzoxazepinone, U Siena |
D5, artificial gp41 MAb, Merck |
|
Thiovir, foscarnet analog, Adventrx
|
Thiazol derivatives, Inst for Virus Research, Japan |
|
|
Herpesvirus saimiri, transcription and post-transcription antiviral, Temple U
|
Methyl derivatives, U South Denmark |
|
|
Triol, diterpine RTI, Cruz Foundation, Brasil
|
MV026048 and MIV-170, Medivir |
|
|
Stampidine, Parker Hughes Institute
|
Phenylthiazoylamines, Yale U
|
|
|
Branched 3 primers, U Illinois |
pyridinone derivatives, Rutgers |
|
|
dTTP, U Rochester |
|
|
|
E2-FdA, Kumamoto U
|
|
|
|
DOT, dioxolane thymidine, U Georgia |
|
|
|
R12-2, thioaptamer, RNaseH domain blocker, U Texas |
|
|
|
Didox, Ribonucleotide reductase (RR) inhibitor, Molecules for Health |
|
|
| Phase I |
KP-1461, mutagenic deoxyribo-nucleoside, Koronis
|
|
PPL-100, Ambrilia
|
|
Alovudine (fosalvudine tidoxil, FLT), Heidelberg Pharma |
|
|
| Phase Ib/II |
Racivir (PSI 5004), Pharmasset
|
BILR 355/r, BS, Boehringer Ingelheim
|
|
|
Apricitabine (AVX754), Avexa |
|
|
| |
Elvucitabine (ACH-126), Achillion
|
|
|
| Phase II |
|
Rilpivirine, TMC-278, Tibotec/J&J |
Brecanavir (640385), GSK |
| Phase III |
|
Etravirine (TMC125), Tibotec/J&J |
|
| Notes:
On hold or stopped.
link to abstract/background material from CROI 2005.
link to abstract/background material from XIIIth Conference on Retroviruses and Opportunistic Infections, Denver, US, 5-8 February, 2006.
|
| Entry Inhibitors, Integrase Inhibitors, Maturation Inhibitors and Other Drugs |
| Phase of Development |
Entry Inhibitors* |
Integrase Inhibitors |
Maturation Inhibitors** |
Other |
| Preclinical |
Benzothiepine & Benzazepine derivatives, 11f, and TAK-652, CCR5 antagonists, Takeda
|
L-second generation, Merck
|
enJS56A1, Escape Inhibitor, U Georgia
|
RWJ67567, p38 inhibitor, U Penn / J&J |
|
Betulinic Acid Derivatives (BAD), DSB/U North Carolina
![]() |
Carbazole derivative, NIID, Japan
|
siRNA molecule, CombiMatrix
|
CNI-1493, Rev inhibitor, Heinrich Pette Institute, Germany |
|
Aprepitant, NK-1R antagonist
|
810871, GSK |
Betulinic Acid Derivatives (BAD), U North Carolina |
Trim5α capsid inhibitor, Dana Farber, NIAID
|
|
GBV-C, virus that increases chemokines including RANTES (CCR5 blocker), U Iowa |
Styrylquinoline derivatives, Bioalliance Pharma |
ACH-CIP, capsid inhibitor, Achillion
|
CDK inhibitor,
Gilead |
|
15K & 15D, co-receptor docking inhibitors, NCI |
V-165, Rega Institute, Belgium
|
RPI-MN, ReceptoPharm |
KU-55933, ATM kinase inhibitor, KuDOS Pharma |
|
RC-112 & Retrocyclin-1, θ-Defensins, DASTLR
|
Mycelium integrasone, Fungal polyketide, Merck |
UK-201,844, Pfizer |
RSC-1838, GSK/Shionogi |
|
Indolicidin, NIH |
GS 9224, Gilead Sciences |
siRNA molecule, Nef inhibitor, CombiMatrix |
IM, CDK9 inhibitor, Inst of Human Virology |
|
Pyrrolidine CCR5 receptor antagonists, Merck |
Beta-diketo acids, U Parma/Sassari, Italy |
|
Resveretol, Egr1 gene activator, NCI |
|
IC9564, Duke University
|
PL-2500, P-5-P derivative, Procyon |
|
MDI-P, electrolyzed free radical, Medical Discoveries |
|
Zinc Finger Protein Nucleases, CCR5 inhibitors, Sangamo Biosciences |
Monophores, Sunesis |
|
Poly (acrylic) acid, Chinese Academy of Science |
|
MDX-010, anti-CTLA-4 antibody, Medarex |
AVX-I, Avexa |
|
α-v integrins, irsiCaixa Foundation/Merck |
|
UMIST, Genetic Innovation Network
|
Theophylline, caffeine-related methylxanthine, Thomas Jefferson U
|
|
CNI-1493, Rev inhibitor, Cytokine Pharmasciences |
|
NB-2 and NB-64, gp41 coiled coil blocker, Shibo & Kumar |
ITI-367, Oxadiazol pre-integrase inhibitor, GWU
|
|
Curcumin (diferuloylmethane), Tat inhibitor, Jawaharlal Nehru Center, India |
|
AMD-887, CCR5 antagonist, Anormed
|
Triketoacid IIs, BMS |
|
(12) rev inhibitors, NIH |
|
KD-247, CCR5 inhibitor, Kumamoto U |
|
|
Glycodendrimers, lipid raft carbohydates, Penn State |
|
SP01A & SP10, entry inhibitors, Samaritan |
|
|
siRNA constructs, rev/tat inhibitors, Beckman Institute
|
|
gp120-gp41 disulfide bond, Amsterdam MC, Cornell U, U Illinois Chicago |
|
|
HRG214, caprine IgG, Virionyx, New Zealand |
|
NSC 13778, gp120 blockers, SAIC-NCI |
|
|
RPI, nicotinic acetylcholine receptor blocker, NutraPharma |
|
sifuvirtide, fusion inhibitor, Fusogen
|
|
|
Oxadiazols, nuclear localization viral matrix blockers, International Therapeutics |
|
gp41 inhibitors, New York Blood Center
|
|
|
LEDGF-integrase competers, Catholic U Leuven, Belgium |
|
gp41 inhibitors, Locus Pharmaceuticals |
|
|
SCY-635, Cyclophilin Inhibitor, Scynexis |
|
AMD-3451, CCR5/CXCR4 receptor antagonist, Anormed |
|
|
|
|
Monoclonal FAbs, gp41 blocker, NIH |
|
|
|
|
DP-178, fusion inhibitor, Weizmann Institute |
|
|
|
|
TR-999 and TR-1144, Trimeris/Roche |
|
|
|
|
KRH-3955 and KRH-3140, CXCR4 inhibitors, Kureha Corp |
|
|
|
|
Peptidic CCR5 inhibitor, Selexis |
|
|
|
|
Small molecule gp120 inhibitors, BMS |
|
|
|
|
INCB15050, CCR5 inhibitor, Incyte |
|
|
|
|
HGS101, CCR5 mAb, Human Genome Sciences |
|
|
|
|
ZFN, CCR5 disrupter, Sangamo BioSciences |
|
|
|
|
ROAbs, CCR5 mAbs, Roche |
|
|
|
| Phase I |
BMS-378806, gp120 blocker, BMS
|
GSK364735, GSK/Shionogi |
|
BI-201, Tat inhibiting mAb, BioInvent |
|
TAK-652, Takeda |
|
|
|
|
004, mAB, Human Genome Sciences |
|
|
|
|
Suc-HSA, fusion inhibitor, Sanquin |
|
|
|
| Phase I/II or Phase IB |
AMD-070, CXCR4 antagonist, Anormed |
|
|
Valproic acid, [Depakote™, Abbott], ACTG |
|
PRO-140, MAb,
Progenics
|
|
|
|
|
INCB9471, CCR5 inhibitor, Incyte |
|
|
|
|
HGS004, CCR5 mAb, Human Genome Sciences |
|
|
|
| Phase II |
Vicriviroc, CCR5 antagonist, Schering Plough |
GS-9137, Gilead |
|
Bevirimat (PA-457), Budding inhibitor, Panacos |
|
TNX-355, Anti-CD4 MAb, Tanox/Biogen |
|
|
|
| Phase III |
Maraviroc, CCR5 antagonist, Pfizer
|
MK-0518, Merck |
|
|
| Notes:
* entry inhibitors, including CCR5 and CXCR4 receptor binding antagonists and CD4 monoclonal antibodies directed at binding, fusion, and entry.
** includes the later replication stages of Assembly, Budding, and Maturation.
On hold or stopped.
link to abstract/background material from CROI 2005.
link to abstract/background material from XIIIth Conference on Retroviruses and Opportunistic Infections, Denver, US, 5-8 February, 2006.
|
Sửa bởi quản trị viên 20/11/2009 lúc 07:30:36(UTC)
| Lý do: Chưa rõ |
